Verge Labs, a frontier AI lab for human disease biology, and commercial-stage biopharmaceutical company Tenacia Biotechnology announced on Tuesday a strategic platform partnership to advance Tenacia's pipeline for central nervous system (CNS) diseases.

Under the agreement, Verge will leverage its platform and proprietary multimodal human tissue data to prioritise and characterise targets for selected Tenacia programmes, grounding Tenacia's development decisions in human brain biology. The work pairs Verge's platform with Tenacia's internal development and disease expertise.

Verge Labs is built on a multimodal CNS patient dataset of more than 12,000 brain transcriptomes across 6,500 patients, with matched single-cell, proteomic, genomic and clinical data. Drug developers use the platform to answer translational questions that determine a programme's likelihood of success in the clinic – how a target behaves in human tissue, which preclinical models best predict human response, what a target's mechanism of action is, which biomarkers track its activity, and which patients are most likely to respond – grounding those decisions in direct human evidence before substantial resources are committed.